Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns

Feb 22 2017

• By Brenda Sandburg

FDA entrance sign 2016

Related Content

FDA Measures Naloxone Price Trend In Considering Wider Availability

Jul 09 2015

Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA

Oct 12 2016

Higher Naloxone Doses Narrowly Favored By FDA Panel

Oct 06 2016

Related Companies

Amphastar Pharmaceuticals, Inc.

Adapt Pharma Limited

Endo, Inc.

Kaléo Pharmaceutical Inc.

Pfizer Inc.

Viatris Inc.

Additional Topics

United States FDA Complete Response Letters BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window